UNLABELLED We compared functional imaging modalities including PET with 6-(18)F-fluorodopamine ((18)F-DA) with (123)I-metaiodobenzylguanidine ((123)I-MIBG) and somatostatin receptor scintigraphy (SRS) with (111)In-pentetreotide in nonmetastatic and metastatic pheochromocytoma (PHEO). METHODS We studied 25 men and 28 women (mean age +/- SD, 44.2 +/- 14.2 y) with biochemically proven nonmetasta...

Received 11/13/2000; revised 2/1/2001; accepted 2/5/2001. For correspondence or reprints contact: Chiang-Hsuan Lee, M.D., Department of Nuclear Medicine, Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niao Sung Hsiang, Kaohsiung Hsien, Taiwan, Tel: (886)7-7317123 ext. 2627, Fax: (886)77317123 ext. 2631, E-mail: [email protected] Background: This study aimed to evaluate the efficacy of io...

A 6-year-old boy with ganglioneuroblastoma, received 4 courses of chemotherapy and underwent partial resection the tumor. The control scintigraphy 123 I-metaiodobenzylguanidine ( I-mIBG) was performed, including single photon emission computed tomography protocol combined (SPECT/CT), revealing residual tumor pathological uptake I-MIBG. In addition to this, there a focal I-mIBG in gallbladder. t...

The purpose of the study was; (i) to determine whether 123I-MIBG scintigraphy is sensitive for detection of amiodarone induced pulmonary toxicity (AIPT) and (ii) to compare it with 99mTc-DTPA radioaerosol. Twelve white New Zealand rabbit with initial mean body weight 4.24 +/- 0.47 g were divided into two groups. AIPT group (n = 7) was administered amiodarone (20 mg/kg BW). The control group (n ...

I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy can be used to assess the pathophysiology of postganglionic presynaptic cardiac sympathetic nerve endings and is the most frequently used imaging agent to assess cardiac sympathetic innervation. In 1994, Hakusui et al were the first to report reduced cardiac MIBG and preserved thallium accumulation in Parkinson’s disease (PD). Subsequently,...

BACKGROUND Recommendations on the use of I-123 metaiodobenzylguanidine (MIBG) scintigraphy in localising phaeochromocytomas vary. The accuracy of I-123 MIBG scintigraphy was determined by evaluating our own I-123 MIBG scans and performing a meta-analysis. MATERIALS AND METHODS Between January 1992 and May 2002, the I-123 MIBG scans of consecutive patients suspected of a phaeochromocytoma were...

A decreased cardiac (123)I-metaiodobenzylguanidine ((123)I-MIBG) uptake has been used as a powerful tool to identify Lewy body disease, such as idiopathic parkinson's disease (IPD). We performed cardiac (123)I-MIBG scintigraphy in patient with autosomal recessive juvenile parkinsonism (ARJP) with parkin gene mutation (PARK2). The findings showed normal cardiac (123)I-MIBG uptake. Therefore, alt...

BACKGROUND We aimed to evaluate the utility of the combined use of cardiac 123I-metaiodobenzylguanidine (MIBG) scintigraphy, olfactory testing, and substantia nigra (SN) hyperechogenicity on transcranial sonography (TCS) in differentiating Parkinson's disease (PD) from atypical parkinsonian syndromes (APSs), such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). METHO...

(123)I-ioflupane SPECT (DaTscan) is an examination that detects presynaptic dopamine neuronal dysfunction, and has been used as a diagnostic tool to identify degenerative parkinsonism. Additionally, myocardial (123)I-metaiodobenzyl guanidine (MIBG) scintigraphy measures the concentration of cardiac sympathetic nerve fibers and is used to diagnose Parkinson's disease (PD). These exams are used a...

Background: Because patients with idiopathic Parkinson’s disease (PD) may exhibit patterns of cognitive impairment, it is difficult to distinguish from patients with Parkinson's disease dementia (PDD). Recently, cardiac I-metaiodobenzylguanidine (MIBG) scintigraphy has been used to help distinguish PD from atypical Parkinsonism. This study investigated the relations between cardiac I-MIBG scint...